Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

Table of Contents

October 1, 2021; Volume 62,Issue 10

This Month in JNM

  • You have access
    This Month in JNM
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 8A;

The State of the Art

  • You have access
    Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
    Sonya Park, Ashwin Singh Parihar, Lisa Bodei, Thomas A. Hope, Nadine Mallak, Corina Millo, Kalpna Prasad, Don Wilson, Katherine Zukotynski and Erik Mittra
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1323-1329; DOI: https://doi.org/10.2967/jnumed.120.251512

Hot Topics

  • You have access
    Artificial Intelligence for PET Image Reconstruction
    Andrew J. Reader and Georg Schramm
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1330-1333; DOI: https://doi.org/10.2967/jnumed.121.262303

Continuing Education

  • You have access
    PET/MRI Improves Management of Children with Cancer
    Lucia Baratto, K. Elizabeth Hawk, Lisa States, Jing Qi, Sergios Gatidis, Louise Kiru and Heike E. Daldrup-Link
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1334-1340; DOI: https://doi.org/10.2967/jnumed.120.259747

Focus on Molecular Imaging

  • You have access
    The Latest Advances in Imaging Crosstalk Between the Immune System and Fibrosis in Cardiovascular Disease
    Gyu Seong Heo, Lanlan Lou, Deborah Sultan and Yongjian Liu
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1341-1346; DOI: https://doi.org/10.2967/jnumed.120.255539

Editorial

  • You have access
    Imaging of Small Intestine Neuroendocrine Neoplasms: Is SSTR PET the Holy Grail?
    Alessio Imperiale, Leah Meuter, Karel Pacak and David Taïeb
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1347-1348; DOI: https://doi.org/10.2967/jnumed.121.262140

Oncology

  • Clinical

    • Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, <sup>18</sup>F-FMISO PET, and <sup>18</sup>F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Open Access
      Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, 18F-FMISO PET, and 18F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Solène Collet, Jean-Sébastien Guillamo, David Hassanein Berro, Ararat Chakhoyan, Jean-Marc Constans, Emmanuèle Lechapt-Zalcman, Jean-Michel Derlon, Mathieu Hatt, Dimitris Visvikis, Stéphane Guillouet, Cécile Perrio, Myriam Bernaudin and Samuel Valable
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1349-1356; DOI: https://doi.org/10.2967/jnumed.120.249524
    • Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region
      You have access
      Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region
      Danique M.S. Berger, Nynke S. van den Berg, Vincent van der Noort, Bernies van der Hiel, Renato A. Valdés Olmos, Tessa A. Buckle, Gijs H. KleinJan, Oscar R. Brouwer, Lenka Vermeeren, Baris Karakullukçu, Michiel W.M. van den Brekel, Bart A. van de Wiel, Omgo E. Nieweg, Alfons J.M. Balm, Fijs W.B. van Leeuwen and W. Martin C. Klop
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1357-1362; DOI: https://doi.org/10.2967/jnumed.120.246819
    • Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer
      You have access
      Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer
      Elio Mazzone, Paolo Dell’Oglio, Nikos Grivas, Esther Wit, Maarten Donswijk, Alberto Briganti, Fijs Van Leeuwen and Henk van der Poel
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1363-1371; DOI: https://doi.org/10.2967/jnumed.120.259788
    • Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of <sup>18</sup>F-FDG–Avid Lymphomas: A Prospective Study
      You have access
      Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of 18F-FDG–Avid Lymphomas: A Prospective Study
      Lara Marchetti, Luca Perrucci, Fabio Pellegrino, Luca Baroni, Annalisa Merlo, Massimo Tilli, Ilaria Rambaldi, Elisa Maietti, Aldo Carnevale, Mirco Bartolomei and Melchiore Giganti
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1372-1379; DOI: https://doi.org/10.2967/jnumed.120.259242
    • BRIEF COMMUNICATION

      • Prognostic Value of Bone Marrow Metabolism on Pretreatment <sup>18</sup>F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
        You have access
        Prognostic Value of Bone Marrow Metabolism on Pretreatment 18F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
        Ryusuke Nakamoto, Lisa C. Zaba, Tie Liang, Sunil Arani Reddy, Guido Davidzon, Carina Mari Aparici, Judy Nguyen, Farshad Moradi, Andrei Iagaru and Benjamin Lewis Franc
        Journal of Nuclear Medicine October 1, 2021, 62 (10) 1380-1383; DOI: https://doi.org/10.2967/jnumed.120.254482
  • Basic

    • Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      You have access
      Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Kelly E. Henry, Travis M. Shaffer, Kyeara N. Mack, Janine Ring, Anuja Ogirala, Susanne Klein-Scory, Christina Eilert-Micus, Wolff Schmiegel, Thilo Bracht, Barbara Sitek, Marguerite Clyne, Colm J. Reid, Bence Sipos, Jason S. Lewis, Holger Kalthoff and Jan Grimm
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1384-1390; DOI: https://doi.org/10.2967/jnumed.120.256776

Theranostics

  • Clinical

    • BRIEF COMMUNICATION

      • First-in-Humans Application of <sup>161</sup>Tb: A Feasibility Study Using <sup>161</sup>Tb-DOTATOC
        You have access
        First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC
        Richard P. Baum, Aviral Singh, Harshad R. Kulkarni, Peter Bernhardt, Tobias Rydén, Christiane Schuchardt, Nadezda Gracheva, Pascal V. Grundler, Ulli Köster, Dirk Müller, Michael Pröhl, Jan Rijn Zeevaart, Roger Schibli, Nicholas P. van der Meulen and Cristina Müller
        Journal of Nuclear Medicine October 1, 2021, 62 (10) 1391-1397; DOI: https://doi.org/10.2967/jnumed.120.258376
    • FEATURED ARTICLE OF THE MONTH

      • A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of <sup>68</sup>Ga-NODAGA-LM3 and <sup>68</sup>Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
        You have access
        A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
        Wenjia Zhu, Yuejuan Cheng, Ru Jia, Hong Zhao, Chunmei Bai, Jianming Xu, Shaobo Yao and Li Huo
        Journal of Nuclear Medicine October 1, 2021, 62 (10) 1398-1405; DOI: https://doi.org/10.2967/jnumed.120.253096
    • Quantitative <sup>68</sup>Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATE
      You have access
      Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
      Claudia Ortega, Rebecca K.S. Wong, Josh Schaefferkoetter, Patrick Veit-Haibach, Sten Myrehaug, Rosalyn Juergens, David Laidley, Reut Anconina, Amy Liu and Ur Metser
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1406-1414; DOI: https://doi.org/10.2967/jnumed.120.256727
    • Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      You have access
      Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Johannes Duell, Franziska Krummenast, Andreas Schirbel, Philipp Klassen, Samuel Samnick, Hilka Rauert-Wunderlich, Leo Rasche, Andreas K. Buck, Hans-Jürgen Wester, Andreas Rosenwald, Herrmann Einsele, Max S. Topp, Constantin Lapa and Malte Kircher
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1415-1421; DOI: https://doi.org/10.2967/jnumed.120.257279
    • Matched-Pair Comparison of <sup>18</sup>F-DCFPyL PET/CT and <sup>18</sup>F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions
      You have access
      Matched-Pair Comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions
      Maurits Wondergem, Friso M. van der Zant, Wouter A.M. Broos and Remco J.J. Knol
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1422-1429; DOI: https://doi.org/10.2967/jnumed.120.258574
    • Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      You have access
      Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Katherine A. Zukotynski, Urban Emmenegger, Sebastien Hotte, Anil Kapoor, Wei Fu, Amanda L. Blackford, John Valliant, François Bénard, Chun K. Kim, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Kenneth J. Pienta, Michael A. Gorin, Matthew Lubanovic, Jihyun Kim, Martin G. Pomper, Steve Y. Cho and Steven P. Rowe
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1430-1437; DOI: https://doi.org/10.2967/jnumed.120.259069
    • INVITED PERSPECTIVE

      • You have access
        RESIST-PC: U.S. Academic Foray into PSMA Theranostic Trials
        Amir Iravani and Thomas A. Hope
        Journal of Nuclear Medicine October 1, 2021, 62 (10) 1438-1439; DOI: https://doi.org/10.2967/jnumed.121.262602
    • Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      You have access
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982
    • You have access
      Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
      Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
    • BRIEF COMMUNICATION

      • Head-to-Head Comparison of <sup>68</sup>Ga-NOTA (<sup>68</sup>Ga-NGUL) and <sup>68</sup>Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
        You have access
        Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
        Minseok Suh, Hyung-Jun Im, Hyun Gee Ryoo, Keon Wook Kang, Jae Min Jeong, Sneha Prakash, Sanjana Ballal, Madhav P. Yadav, Chandrasekhar Bal, Chang Wook Jeong, Cheol Kwak and Gi Jeong Cheon
        Journal of Nuclear Medicine October 1, 2021, 62 (10) 1457-1460; DOI: https://doi.org/10.2967/jnumed.120.258434
  • Basic

    • FEATURED BASIC SCIENCE ARTICLE

      • Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
        You have access
        Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
        Ann-Christin Eder, Martin Schäfer, Jana Schmidt, Ulrike Bauder-Wüst, Mareike Roscher, Karin Leotta, Uwe Haberkorn, Klaus Kopka and Matthias Eder
        Journal of Nuclear Medicine October 1, 2021, 62 (10) 1461-1467; DOI: https://doi.org/10.2967/jnumed.120.248443
    • Utility of <sup>211</sup>At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model
      You have access
      Utility of 211At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model
      Huizi Keiko Li, Yukie Morokoshi, Satoshi Kodaira, Tamon Kusumoto, Katsuyuki Minegishi, Hiroaki Kanda, Kotaro Nagatsu and Sumitaka Hasegawa
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1468-1474; DOI: https://doi.org/10.2967/jnumed.120.249300
    • Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
      You have access
      Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
      Patrycja Guzik, Hsin-Yu Fang, Luisa M. Deberle, Martina Benešová, Susan Cohrs, Silvan D. Boss, Simon M. Ametamey, Roger Schibli and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1475-1481; DOI: https://doi.org/10.2967/jnumed.120.255760

Letters to the Editor

  • You have access
    PSMA-Targeted Therapeutics: A Tale About Law and Economics
    Johannes Notni
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1482; DOI: https://doi.org/10.2967/jnumed.121.262308
  • You have access
    Reply: PSMA-Targeted Therapeutics: A Tale About Law and Economics
    Johannes Czernin
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1483; DOI: https://doi.org/10.2967/jnumed.121.262566
  • Open Access
    18F-FDG–Avid Axillary Lymph Nodes After COVID-19 Vaccination
    B. Jake Johnson, Kathryn M. Van Abel, Daniel J. Ma and Derek R. Johnson
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1483-1484; DOI: https://doi.org/10.2967/jnumed.121.262108
  • You have access
    Specific and Nonspecific Uptake in Quantitative 89Zr-Immuno-PET
    Eric Laffon and Roger Marthan
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1484-1485; DOI: https://doi.org/10.2967/jnumed.121.262065

SNMMI Newsline

  • You have access
    SNMMI Newsline
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 11N-22N;
  • You have access
    2021 SNMMI Highlights Lecture: Oncology and Therapy, Part 1
    Heiko Schöder
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 9N-15N;
  • You have access
    SNMMI and ACGME Equity Matters Initiative
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 15N;
  • You have access
    Amnon (Amy) Piepsz, MD (1938–2021)
    Alain Prigent, M. Donald Blaufox, Andrew Taylor and Naomi Alazraki
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 16N;
  • You have access
    State of the Society: SNMMI Thrives Despite COVID-19 Challenges
    Virginia Pappas
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 17N;
  • You have access
    Newsbriefs
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 18N-20N;
Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine: 62 (10)
Journal of Nuclear Medicine
Vol. 62, Issue 10
October 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)

Issue highlights

  • A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
  • Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
Sign up for alerts

Jump to

  • This Month in JNM
  • The State of the Art
  • Hot Topics
  • Continuing Education
  • Focus on Molecular Imaging
  • Editorial
  • Oncology
    • Clinical
      • BRIEF COMMUNICATION
    • Basic
  • Theranostics
    • Clinical
      • BRIEF COMMUNICATION
      • FEATURED ARTICLE OF THE MONTH
      • INVITED PERSPECTIVE
      • BRIEF COMMUNICATION
    • Basic
      • FEATURED BASIC SCIENCE ARTICLE
  • Letters to the Editor
  • SNMMI Newsline
  • Most Cited
  • Most Read
Loading
  • Total-Body PET Multiparametric Imaging of Cancer Using a Voxelwise Strategy of Compartmental Modeling
  • Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients
  • 68Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the 68Ga-FAPI PET Prospective Observational Trial
  • Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial
  • Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results
More...
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire